SLL

ZYDELIG® for
relapsed SLL

after ≥2 systemic
therapies

ZYDELIG achieved 58% ORR in a pivotal phase 2 open-label trial (95% CI, 37%-77%) 0% CR, 58% PR; n=26

Accelerated approval was granted for SLL based on overall response rate. An improvement in patient survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

ZYDELIG is not indicated or recommended for first-line treatment of any patient.